Select region:

Clinical trials located in

Liège

Liège city is located in Belgium. Currently, 20 clinical trials are being conducted in this city.

Liège, nestled in Belgium’s Wallonia region, is a city steeped in history and culture. Known for its vibrant arts scene, Liège boasts the Royal Opera of Wallonia and numerous museums, including the Grand Curtius. The city’s architectural marvels, such as the Prince-Bishops’ Palace and the modern Calatrava-designed Liège-Guillemins railway station, showcase its rich past and forward-thinking ethos. Liège is also celebrated for its culinary delights, including the famous Liège waffle. The annual 15th of August festival highlights its folklore and traditions, making it a hub of Walloon culture.

  • CT-EU-00057838

    Testing the effectiveness and safety of povorcitinib in Asthma control

    This study involves an investigation into a medication known as povorcitinib, aimed at assessing its potential benefits for individuals with moderate to severe asthma whose current management is inadequate. The study adopts a ‘double-blind’ approach, ensuring that neither the participant nor the doctor is aware of whether the individual is receiving the actual drug or a placebo – a treatment resembling the drug but lacking any active substance. The focus lies in observing the impact of povorcitinib on lung function over a period of up to 24 weeks, with particular attention to the potential exacerbation of asthma symptoms.

    BelgiumGermanyPolandSpain
  • Extended safety study for participants using spartalizumab alone or combined

    This study relates to a type of medication called spartalizumab. The goal is to find out if this medicine, when given alone or with other treatments, is safe and doesn’t cause any unwanted side effects. The study is open to people who have already been involved in past studies for spartalizumab. The reason for this is to keep giving these people access to the treatment while also continuously assessing its safety.

    BelgiumCzechiaGermanyItalySpain
  • Testing tozorakimab’s effect on chronic lung disease symptoms

    This study is all about testing a new drug, Tozorakimab, for people who have COPD – a lung disease that makes it difficult to breathe—and have had a bad flare-up in the past year. The researchers will give some people the new drug and some people a placebo (a dummy treatment) and see which works best. The drug is delivered in a shot under the skin, and all the people in the study will also keep taking their usual COPD medicines. The main things the researchers will be looking at are whether the new drug can reduce the number of flare-ups, improve quality of life (measured using a questionnaire), reduce the need for rescue medication and if it changes the results of breathing tests.

    BelgiumFranceGermanyGreeceHungaryItalyNetherlandsSpainUnited Kingdom
  • Advanced colon cancer treatment trial using ompenaclid

    This study explores a new treatment approach for advanced colorectal cancer by combining ompenaclid with standard chemotherapy (FOLFIRI and bevacizumab). It aims to improve outcomes for patients with RAS mutant tumors. Participants receive either ompenaclid or a placebo alongside standard chemotherapy. The study focuses on tumor response and overall survival, hoping to provide a more effective treatment option for those battling this challenging form of cancer.

    BelgiumFranceSpain
  • A study on crovalimab in children with aHUS

    This study is about testing a medicine called Crovalimab in children who have a blood and kidney disease called Atypical Hemolytic Uremic Syndrome or aHUS for short. This trial is going to answer two key questions – is Crovalimab effective in treating aHUS and is it safe for kids to use without damaging side effects? The doctors will also be looking at how the child’s body handles the medicine, like how it gets absorbed, breaks down, and gets removed from their body. This helps figure out how often the medicine should be given for it to work best.

    BelgiumFranceHungaryItalyPolandSpain
  • Examining povorcitinib for treating hidradenitis suppurativa

    This study is about a drug called Povorcitinib, also known as INCB054707. It’s being tested on people who have moderate to severe Hidradenitis Suppurativa (HS), a painful skin condition. The trial will last for 12 weeks, and then there will be an extension period of 42 weeks. The aim of the trial is to see whether the drug is both safe, and effective enough to reduce the symptoms by at least 50%, without increasing certain symptoms like abscesses or tunnels formed by the disease. The study will also look at whether the drug significantly reduces skin pain and improves quality of life.

    AustriaBelgiumCzechiaFranceGermanyGreeceNetherlandsPolandSpain
  • Testing new treatment for Geographic Atrophy treatment

    This research study pertains to a condition affecting the eyes known as Geographic Atrophy (GA), stemming from the aging process (Age-related Macular Degeneration). The investigation aims to assess the potential efficacy of a new drug (JNJ-81201887), administered through intraocular injection, in improving the aforementioned condition. A comparative analysis will be conducted between individuals receiving the drug and those subjected to a placebo procedure (a simulated intervention lacking an actual drug). Specialized photographs will be taken to quantify any alterations in the condition over an 18-month period. Additionally, observations will be made regarding changes in distant visual acuity, reading ability, and the requirement for aids during these activities over time. Ultimately, the study will examine the impact of the eye condition on daily activities.

    BelgiumCzechiaDenmarkGermanyHungaryItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Study of alpelisib and fulvestrant for advanced breast cancer treatment

    This trial is looking at the effects of the combined use of two drugs, alpelisib and fulvestrant, in treating patients who have advanced breast cancer. The cancer should be HR-positive and HER2-negative, and have a specific mutation (PIK3CA). If the patients already underwent certain other treatments like CDK4/6 Inhibitors and aromatase Inhibitors, but the cancer has progressed, they could join this trial. Doctors will be able to compare the results of patients taking alpelisib and fulvestrant together, with those taking fulvestrant with a placebo, They aim to check which combination works better in delaying the advance of cancer or in improving a patient’s life duration.

    BelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyPolandPortugalRomaniaSlovakiaSpain
  • Continuing sickle cell treatment with crizanlizumab

    This study is for people with Sickle Cell Disease who have already been part of an earlier Novartis study about a medicine called crizanlizumab. After signing up, patients can get the medicine as soon as possible, following the same schedule as in the last study. Patients will be checked on 105 days after their last dose for their safety, unless they keep getting the medicine afterward. They plan to keep the study going for 10 years, or until the medicine is available to buy and is covered by health insurance. The aim is to let people who found the earlier study helpful have continued access to this medicine if they can’t get it otherwise. The researchers will also be recording any side effects people have while on this medicine.

    BelgiumFranceGermanyItalySpain
  • Studying the safety and effectiveness of a new drug for ulcerative colitis

    This study focuses on examining a drug called ABBV-668, administered in oral capsules, to evaluate its safety and effectiveness in the treatment of adults with ulcerative colitis, a gastrointestinal disease characterized by bleeding and inflammation in the large intestine. About 40 participants will take the capsules twice a day for 16 weeks. After this treatment period, doctors will continue to monitor participants for an additional month. The study involves visiting a doctor more often than usual, carefully checking for potential side effects, and asking participants-specific questions. To measure changes in participants’ condition, doctors will use a special scoring system.

    BelgiumFrancePoland
  • Study of nivolumab + relatlimab for new advanced melanoma cases

    The study explores the effects of combining Nivolumab and Relatlimab, given subcutaneously, in treating melanoma that hasn’t been treated before and can’t be surgically removed. The focus is on the medication levels in the blood and comparing the treatment’s impact on the disease with standard methods​​.

    AustriaBelgiumCzechiaFinlandFranceGermanyItalyNorwayPolandSpainSwedenUnited Kingdom
  • Study testing Ruxolitinib cream for Prurigo Nodularis treatment

    This study is testing a cream with Ruxolitinib to see if it’s safe and effective for people with a skin condition called Prurigo Nodularis (PN). The study has three main parts. In the first 12 weeks, participants will receive either the cream with Ruxolitinib or placebo (also known as vehicle-controlled) treatment. After that, all participants will receive the cream with Ruxolitinib for another 40 weeks. After that, there will be an extra 30 days to keep an eye on safety. The trial will measure success by checking if the cream can reduce itchiness. Treatment success will be evaluated by medical professionals, considering factors such as the number of skin nodules and the extent of redness and crusting in the condition’s severity.

    BelgiumFranceGermanyItalyNetherlandsPolandSpain
  • Continued study of ozanimod for severe Crohn’s Disease

    This research is about an extended study on the use of an oral medication named Ozanimod for people suffering from Crohn’s disease. Crohn’s disease can make the stomach and intestines really uncomfortable, causing swellings and pain. The main aim of this study is to check if this medicine, Ozanimod, is safe for intake and how effective it is in easing these uncomfortable feelings in the stomach. The researchers will rate patients’ illnesses using the Crohn’s Disease Activity Index (a measurement tool).

    BelgiumBulgariaCzechiaFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Study on a new combination therapy for active ulcerative colitis

    This study aims to assess the effectiveness and safety of new combination therapy with JNJ-78934804 (Guselkumab/Golimumab) in comparison to guselkumab and golimumab administred alone for individuals with moderately to severely active ulcerative colitis. Participants who have shown inadequate response, loss of response, or intolerance to approved advanced therapies will be included. The trial includes various treatment groups: placebo, Guselkumab, Golimumab, and different doses of JNJ-78934804. All participants meeting inadequate response criteria will be escalated to an active treatment. The study will last for 48 weeks and the progress will be tracked over this period. The primary focus is to evaluate the efficacy and safety of the different doses of new therapy in managing ulcerative colitis over the course of the study.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalSlovakiaSloveniaSpainSwedenUnited Kingdom
  • Studying ozanimod as ongoing treatment for Severe Crohn’s Disease

    This trial is to test a medication called Ozanimod on people who have a serious type of Crohn’s Disease. Crohn’s Disease can make the stomach hurt a lot and sometimes makes difficulty eating.  The researchers want to see if the medication helps to calm the disease, so patients feel better. Some patients will get the Ozanimod and others will get a placebo.  The researchers use  ‘Crohn’s Disease Activity Index’ to see how the disease is doing.

    BelgiumBulgariaCzechiaFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Testing tulisokibart’s effects on systemic sclerosis related lung disease

    This is a study about the safety and effectiveness of a drug called tulisokibart for people with a specific lung disease often seen in patients with a disease called systemic sclerosis. The lung disease makes it hard for them to breathe because their lung tissues are becoming thick and hard. In this trial, some patients will get tulisokibart and others will get a placebo (a pill without any active medicine). Everyone will be watched closely for any negative reactions, such as unwanted symptoms or health problems. To check how well the drug works, they there will be done a few tests.

    BelgiumFranceGermanyHungaryItalyNetherlandsNorwayPolandSpainUnited Kingdom
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Testing Milvexian’s effectiveness in preventing repeat strokes

    This research trial, called LIBREXIA-STROKE, will test a medication called Milvexian on those who have recently had a stroke or a high-risk ‘mini-stroke’. In its 3rd testing phase, the study will involve a system where the patients won’t know whether they are receiving the actual drug or a substitute with no effect, referred to as a ‘placebo’, to maintain fairness. Milvexian is a medication that can potentially reduce the risk of having another stroke, and this trial aims to observe how effective it is in doing so. The trial will look at when the first stroke happens after starting the trial, if other major heart or limb diseases occur, or if strokes occur in the first 90 days.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom

See more clinical trials in other cities in Belgium:

.